SEC Form 10-K filed by Neuphoria Therapeutics Inc.
$NEUP
Biotechnology: Pharmaceutical Preparations
Health Care
Unavailable
Unavailable
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
4 - Neuphoria Therapeutics Inc. (0001191070) (Issuer)
3 - Neuphoria Therapeutics Inc. (0001191070) (Issuer)
4 - Neuphoria Therapeutics Inc. (0001191070) (Issuer)
BURLINGTON, Mass., Oct. 27, 2025 (GLOBE NEWSWIRE) -- Neuphoria Therapeutics Inc. ("Neuphoria" or the "Company") (NASDAQ:NEUP), a clinical-stage biotechnology company developing impactful treatments for neuropsychiatric disorders, today announced that its Board of Directors (the "Board") has determined to adopt a limited-duration stockholder rights plan (the "Rights Plan"), effective immediately. The Board adopted the Rights Plan in response to significant and rapid accumulations of the Company's publicly traded common stock by certain investors. The Rights Plan is intended to protect the interests of the Company and its stockholders, help ensure that all interested parties have the oppo
AFFIRM-1 trial did not meet primary endpoint or secondary endpoints Company to conduct strategic review of portfolio and business operations BURLINGTON, Mass., Oct. 20, 2025 (GLOBE NEWSWIRE) -- Neuphoria Therapeutics Inc. (NASDAQ:NEUP) ("Neuphoria" or the "Company"), a clinical-stage biotechnology company developing impactful treatments for neuropsychiatric disorders, today announced that the AFFIRM-1 Phase 3 trial of BNC210 for the acute treatment of social anxiety disorder (SAD) did not meet its primary endpoint of change from baseline to the average of the performance phase of the public speaking challenge in Subjective Units of Distress Scale (SUDS) scores. In addition, analyses of s
Last patient last visit (LPLV) milestone in AFFIRM-1 Phase 3 trial of BNC-210 in social anxiety disorder (SAD) achieved; topline readout anticipated in early Q4 2025 Cash runway extended through fiscal Q2 2027 BURLINGTON, Mass., Sept. 29, 2025 (GLOBE NEWSWIRE) -- Neuphoria Therapeutics Inc. (NASDAQ: NEUP) ("Neuphoria" or the "Company"), a clinical-stage biotechnology company developing impactful treatments for neuropsychiatric disorders, today reported its financial results for its fiscal year ended June 30, 2025, and provided recent business updates. "It is an exciting time for Neuphoria as we rapidly approach topline data from our AFFIRM-1 Phase 3 study of BNC-210 in social anxiety di
8-K - Neuphoria Therapeutics Inc. (0001191070) (Filer)
424B5 - Neuphoria Therapeutics Inc. (0001191070) (Filer)
8-K - Neuphoria Therapeutics Inc. (0001191070) (Filer)
4 - Neuphoria Therapeutics Inc. (0001191070) (Issuer)
BURLINGTON, Mass., Oct. 27, 2025 (GLOBE NEWSWIRE) -- Neuphoria Therapeutics Inc. ("Neuphoria" or the "Company") (NASDAQ:NEUP), a clinical-stage biotechnology company developing impactful treatments for neuropsychiatric disorders, today announced that its Board of Directors (the "Board") has determined to adopt a limited-duration stockholder rights plan (the "Rights Plan"), effective immediately. The Board adopted the Rights Plan in response to significant and rapid accumulations of the Company's publicly traded common stock by certain investors. The Rights Plan is intended to protect the interests of the Company and its stockholders, help ensure that all interested parties have the oppo